CRSP insider plans sale of 60,000 shares

CRISPR Therapeutics-related Form 144 shows planned insider share sales.

Accepted by SEC EDGAR 01/22/2026 - 05:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CRISPR Therapeutics-related Form 144 shows planned insider share sales. Dr. Samarth Kulkarni has filed notice to sell 60,000 shares of common stock through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $3,648,600. The filing notes that 48,081 shares were acquired on 10/16/2025 and 11,919 shares on 08/15/2025, both as restricted stock awards from the issuer, treated as compensation. It also discloses that during the past three months, Dr. Kulkarni sold 30,000 common shares on 01/20/2026 for gross proceeds of $1,552,593. Shares of the issuer’s common stock outstanding are listed as 95,300,233.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CRSP Form 144 filing disclose about insider share sales?

The Form 144 filing for CRSP discloses that Dr. Samarth Kulkarni intends to sell 60,000 shares of common stock through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $3,648,600.

Who is selling CRSP shares and how many have they recently sold?

Dr. Samarth Kulkarni is the person for whose account the securities are to be sold. In addition to the planned sale of 60,000 common shares, the filing reports a prior sale of 30,000 common shares on 01/20/2026 for gross proceeds of $1,552,593.

How were the CRSP shares in the Form 144 acquired by Dr. Kulkarni?

The shares referenced in the Form 144 were acquired as restricted stock awards from the issuer as compensation. The filing lists 48,081 common shares acquired on 10/16/2025 and 11,919 common shares acquired on 08/15/2025, both labeled as compensation.

What is the outstanding share count referenced in the CRSP Form 144?

The Form 144 lists the number of common shares of the issuer outstanding as 95,300,233. This figure is provided as a baseline share count in the securities information table.

Which broker is handling the planned CRSP share sale in the Form 144?

The planned sale of 60,000 common shares is listed as being handled by Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282, with the securities to be sold on the NASD.

What trading date is indicated for the planned CRSP share sale under Form 144?

The securities information section of the Form 144 states an approximate date of sale of 01/22/2026 for the planned sale of 60,000 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001682019
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CRISPR Therapeutics AG
SEC File Number	001-37923
Address of Issuer	Baarerstrasse 14 Zug SWITZERLAND 6300
Phone	41-041-561-3277
Name of Person for Whose Account the Securities are To Be Sold	Samarth Kulkarni
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	60000	3648600	95300233	01/22/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/16/2025	Acquired as compensation -- Restricted Stock Awards	Issuer			48081	10/16/2025	Compensation
Common	08/15/2025	Acquired as compensation -- Restricted Stock Awards	Issuer			11919	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Dr. Samarth Kulkarni Baarerstrasse 14 Zug V8 6300	Common	01/20/2026	30000	1552593

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 08/27/2025 that is intended to comply with Rule 10b5-1(c).
Date of Notice	01/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/27/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Samarth Kulkarni
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)